Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with ...

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

Basel: Roche has announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to ...

As drug developers seek out novel solutions for geriatric and pediatric populations and patients with difficulty swallowing ...

European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...

The European Commission (EC) has approved a label extension for Roche’s Evrysdi (risdiplam) to include a tablet for people living with SMA.

The tablet formulation can either be swallowed whole ... Genentech’s chief medical officer and head of Global Product Development, said: “The Evrysdi tablet combines established efficacy ...

"Prior 28-day Phase 1 data demonstrated encouraging tolerability with the tablet ... with the development of oral VK2735, Viking is also advancing a subcutaneous formulation of VK2735 through ...

EXTON, PA — Frontage Laboratories, Inc. hosted a grand opening event to unveil its newest Contract Research, Development, and ...